ACE阻害剤市場レポート：動向、予測、競合分析 (2031年まで)

世界のACE阻害剤市場の将来は、心不全、高血圧、慢性腎臓病、糖尿病市場における機会で有望視されています。世界のACE阻害剤市場は、2025年から2031年までのCAGRが3.2%で、2031年までに推定62億米ドルに達すると予想されます。この市場の主な促進要因は、高血圧関連疾患の発生率の上昇、バイオ医薬品製品の開発・生産に対する需要の高まり、心血管疾患の治療改善を目的とした研究開発活動の増加です。

• Lucintelの予測では、薬剤の種類別では、高血圧治療用のリシノプリル医薬品の需要が伸びていることに加え、心臓発作後の生存率向上のためにリシノプリルの使用が増加していることから、予測期間中もリシノプリルが最大セグメントであり続けると思われます。
• 地域別では、アンジオテンシン変換酵素阻害剤に対する需要の増加や、より改良された阻害剤の創出を目的とした研究開発事業の拡大により、北米が予測期間中最大の地域であり続けると思われます。

ACE阻害剤市場の戦略的成長機会

ACE阻害剤市場はダイナミックな成長を遂げており、主要な用途でいくつかの戦略的機会が生まれています。これらの機会は、医学研究の進歩、医療ニーズの進化、心血管疾患に対する世界の意識の高まりによってもたらされています。こうした成長分野を活用することで、利害関係者は市場での存在感を高め、イノベーションを推進することができます。主な用途には、高血圧治療、心不全治療、糖尿病関連疾患、脳卒中予防、慢性腎臓病などがあります。

• 高血圧管理：高血圧管理は依然としてACE阻害剤の主要な用途です。世界の高血圧率の増加に伴い、この分野には大きな成長機会があります。徐放性製剤など製剤の進歩により、患者のアドヒアランスと治療成績が向上しています。高血圧に対する認識とスクリーニング・プログラムの高まりは、効果的なACE阻害剤への需要をさらに高め、大きな市場機会を生み出しています。
• 心不全治療：ACE阻害剤は、世界中で数百万人が罹患している心不全の管理に不可欠です。新たな併用療法や個別化医療の開発により、治療の選択肢が広がっています。ドラッグデリバリーの革新と、心不全管理における有効性の向上を示す新たな臨床データが市場の可能性を高めています。この成長機会は、人口の高齢化と心不全有病率の増加によって後押しされています。
• 糖尿病関連疾患：ACE阻害剤は、糖尿病性腎症などの糖尿病関連合併症の管理に使用されることが多くなっています。糖尿病の世界の有病率の上昇に伴い、糖尿病管理に特化したACE阻害剤の市場が拡大しています。ACE阻害剤の腎機能や心血管の健康に対する保護効果に関する調査が、この機会を後押ししています。糖尿病治療プログラムの拡大や患者の意識の向上も一因となっています。
• 脳卒中の予防：ACE阻害剤の使用による脳卒中の予防は、新たな成長機会です。特に高血圧や心血管疾患を有する患者において、ACE阻害剤が脳卒中リスクの低減に果たす役割を強調する臨床研究が、使用拡大への道を開いています。脳卒中予防戦略がより広範な心血管治療プログラムに組み込まれることが、この市場の成長をさらに後押ししています。
• 慢性腎臓病（CKD）：ACE阻害剤は、特に高血圧や糖尿病を有する患者の慢性腎臓病の管理において重要な役割を果たしています。慢性腎臓病（CKD）の罹患率が世界的に上昇するにつれて、腎保護用に調整されたACE阻害剤に対する需要が高まっています。CKDの進行を遅らせ、患者の予後を改善するACE阻害剤の利点を実証する調査の進展が、この成長機会を後押ししています。

こうした戦略的成長機会は、用途の拡大や治療効果の改善によってACE阻害剤市場を再構築しています。薬剤製剤の革新、個別化医療、糖尿病、脳卒中予防、CKD管理における使用拡大が市場拡大の原動力となっています。こうした機会を活用することで、患者の治療が強化され、市場が大きく成長する可能性があります。

ACE阻害剤市場の促進要因・課題

ACE阻害剤市場は、技術的、経済的、規制的要因が複雑に絡み合って影響を受けています。主な促進要因としては、医薬品開発の進歩、心血管疾患の有病率の増加、医療政策の支援などが挙げられます。逆に、特許切れ、規制上のハードル、市場競争などの課題は市場力学に影響を与えます。これらの要因を理解することは、ACE阻害剤の進化する展望をナビゲートする上で極めて重要です。

ACE阻害剤市場を牽引する要因には、以下のようなものがある：

• 医薬品開発における技術の進歩：新しい製剤やドラッグデリバリーシステムなど、医薬品開発における技術的進歩がACE阻害剤市場を牽引しています。徐放性製剤や併用療法などの技術革新は、薬剤の有効性と患者のコンプライアンスを高めます。これらの進歩により、高血圧や心不全などの疾患のより効果的な管理が可能になり、市場機会の拡大と患者の転帰の改善につながります。
• 心血管疾患の有病率の増加：心血管疾患の世界の有病率の上昇は、ACE阻害剤市場の重要な促進要因です。高血圧、心不全、関連疾患の発生率が高まるにつれて、効果的なACE阻害剤に対する需要が増加しています。また、公衆衛生への取り組みや意識の向上も、診断率や治療率の向上に寄与しており、市場成長の原動力となっています。
• 老年人口の拡大：世界の高齢化がACE阻害剤市場の成長に寄与しています。高齢者は心血管疾患にかかりやすいため、ACE阻害剤の需要が高まっています。医療システムはこの層のニーズに対応するよう適応しており、加齢関連疾患に特化した治療の成長機会を生み出しています。
• 意識の高まりと診断：心血管疾患に対する意識の高まりと診断技術の向上が、ACE阻害剤の需要を牽引しています。スクリーニング・プログラムの充実と患者教育により、高血圧や心不全の早期診断・治療が進んでいます。この動向がACE阻害剤市場を拡大し、患者管理全般を改善しています。
• 支持的な医療政策：各国の医療政策と規制が市場の成長を促進しています。心血管治療へのアクセスを改善し、薬剤費を削減するための政府の取り組みが、ACE阻害剤市場に利益をもたらしています。また、循環器系の研究開発を促進する政策も、市場の拡大と技術革新に寄与しています。

ACE阻害剤市場における課題は以下の通り：

• 特許切れとジェネリック競合：主要なACE阻害剤の特許失効により、ジェネリック医薬品との競合が激化しています。ジェネリック医薬品はコストを削減し、入手しやすさを向上させる一方で、先発医薬品に対する価格圧力にもなっています。製薬会社は、市場シェアを維持するために、新しい製剤や併用療法でイノベーションを起こし、この競合情勢を乗り切らなければならないです。
• 規制上のハードル：新規ACE阻害剤には、長い承認プロセスや厳しい要件などの規制上のハードルが課題となっています。複雑な規制環境に対応することは、市場参入を遅らせ、開発コストを増大させる可能性があります。世界市場で成功するためには、企業は規制に関する専門知識に投資し、国際的に異なる規制に適応する必要があります。
• 市場の飽和：ACE阻害剤市場は、複数のジェネリック医薬品やブランド薬の選択肢があるため、飽和状態にあります。この飽和は利益率の低下やメーカー間の競争激化につながる可能性があります。企業は、混雑した市場で頭角を現すために、革新的な製剤や個別化医療による差別化に注力する必要があります。

ACE阻害剤市場は、市場促進要因・課題が混在して形成されています。技術の進歩、疾病の増加、支援政策が成長を牽引する一方で、特許切れ、規制上のハードル、市場の飽和が障害となっています。成長促進要因を活用しながらこれらの課題に対処することが、市場拡大を維持し、患者ケアを向上させる鍵となります。

目次

第1章 エグゼクティブサマリー

第2章 世界のACE阻害剤市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界のACE阻害剤市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界のACE阻害剤市場：薬剤の種類別
  • リシノプリル
  • ラミプリル
  • カプトプリル
  • モエキシプリル
  • フォシノプリル
  • ペリンドプリル
  • その他
• 世界のACE阻害剤市場：用途別
  • 心不全
  • 高血圧
  • 慢性腎臓病
  • 糖尿病
  • その他
• 世界のACE阻害剤市場：最終用途別
  • 病院
  • 薬局
  • オンラインドラッグストア
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界のACE阻害剤市場：地域別
• 北米のACE阻害剤市場
• 欧州のACE阻害剤市場
• アジア太平洋のACE阻害剤市場
• その他地域のACE阻害剤市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のACE阻害剤市場の成長機会：薬剤の種類別
  • 世界のACE阻害剤市場の成長機会：用途別
  • 世界のACE阻害剤市場の成長機会：最終用途別
  • 世界のACE阻害剤市場の成長機会：地域別
• 世界のACE阻害剤市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のACE阻害剤市場の生産能力拡大
  • 世界のACE阻害剤市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• AstraZeneca
• Abbott
• Bausch Health Companies
• Pfizer
• AbbVie
• Merck
• Novartis
• Johnson & Johnson
• Sanofi
• Eli Lilly and Company International

The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets. The global ACE Inhibitors market is expected to reach an estimated $6.2 billion by 2031 with a CAGR of 3.2% from 2025 to 2031. The major drivers for this market are the rising rates of hypertension-related diseases, the growing demand for biopharmaceutical product development and production, and the increasing number of research and development activities aimed at improving the treatment of cardiovascular diseases.

• Lucintel forecasts that, within the drug type category, lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as the increased use of lisinopril to improve survival after a heart attack.
• In terms of regions, North America will remain the largest region over the forecast period due to the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the ACE Inhibitors Market

The ACE inhibitors market is experiencing several emerging trends driven by advancements in pharmaceutical research, changes in patient demographics, and evolving healthcare policies. These trends are shaping how ACE inhibitors are developed, marketed, and utilized globally. Understanding these trends is crucial for stakeholders to adapt to the changing landscape and address the evolving needs of patients.

• Rise of Generic ACE Inhibitors: The proliferation of generic ACE inhibitors is a significant trend, driven by patent expirations and regulatory approvals. Generic versions offer cost-effective alternatives to branded drugs, increasing accessibility for patients. This trend is fostering competition, reducing drug prices, and expanding market reach, particularly in developing countries. Generic manufacturers are also innovating with new formulations, enhancing drug efficacy and patient compliance.
• Combination Therapies: Combination therapies involving ACE inhibitors and other antihypertensive agents are becoming increasingly popular. These combinations often provide improved efficacy and convenience for patients, addressing multiple aspects of cardiovascular health. The trend reflects a shift towards more personalized and comprehensive treatment regimens, which can lead to better patient outcomes and adherence.
• Technological Advancements in Drug Delivery: Advancements in drug delivery systems, such as extended-release formulations and smart drug delivery mechanisms, are shaping the ACE inhibitors market. These innovations enhance patient compliance by reducing dosing frequency and improving therapeutic outcomes. Technology-driven improvements are making ACE inhibitors more effective and user-friendly, aligning with modern healthcare demands.
• Personalized Medicine: The shift towards personalized medicine is influencing the development of ACE inhibitors tailored to individual patient profiles. Genetic and biomarker research is enabling the creation of ACE inhibitors that address specific patient needs, enhancing treatment efficacy and minimizing side effects. Personalized medicine is expected to drive innovation and improve patient care in the ACE inhibitors market.
• Increased Focus on Preventive Cardiovascular Care: There is a growing emphasis on preventive cardiovascular care, with ACE inhibitors being used more proactively to prevent heart disease and stroke. This trend is supported by rising awareness of cardiovascular risks and preventive health strategies. Preventive use of ACE inhibitors is expanding market opportunities and fostering a proactive approach to cardiovascular health management.

These emerging trends are reshaping the ACE inhibitors market by driving innovation, improving patient outcomes, and expanding market reach. The rise of generics, combination therapies, and technological advancements are making treatments more accessible and effective. Personalized medicine and a focus on preventive care are setting new standards for cardiovascular health management, influencing market dynamics and future developments.

Recent Developments in the ACE Inhibitors Market

The ACE inhibitors market reflects a dynamic environment influenced by regulatory changes, technological advancements, and evolving healthcare needs. These developments are reshaping the landscape of ACE inhibitors, impacting drug availability, pricing, and patient care. Understanding these developments is crucial for stakeholders to navigate the market effectively.

• Approval of New Generics: The approval of new generic ACE inhibitors has intensified market competition and lowered drug prices. Regulatory bodies in various countries have streamlined approval processes for generics, making these cost-effective options more widely available. This development is enhancing patient access to treatment and promoting affordability in the ACE inhibitors market.
• Advances in Drug Formulations: Recent innovations in ACE inhibitor formulations, such as extended-release and combination drugs, have improved patient adherence and treatment outcomes. These advancements allow for less frequent dosing and more effective management of hypertension and heart failure. Enhanced formulations are meeting diverse patient needs and driving market growth.
• Expansion into Emerging Markets: ACE inhibitors are increasingly being introduced into emerging markets, driven by rising healthcare needs and improved access to medical treatments. Companies are focusing on these regions to tap into growing patient populations and address cardiovascular health challenges. This expansion is contributing to global market growth and increased competition.
• Personalized Medicine Approaches: The development of ACE inhibitors tailored to individual genetic profiles represents a significant advancement in personalized medicine. These targeted therapies offer more effective and safer treatment options based on genetic and biomarker information. Personalized approaches are expected to enhance treatment efficacy and patient satisfaction.
• Integration of Digital Health Solutions: The integration of digital health technologies, such as telemedicine and electronic health records, with ACE inhibitors is transforming patient management. Digital solutions facilitate remote monitoring, personalized treatment plans, and improved communication between patients and healthcare providers. This integration is enhancing the overall management of cardiovascular conditions and driving market innovation.

These key developments are impacting the ACE inhibitors market by improving drug accessibility, enhancing treatment options, and expanding market reach. The approval of generics advances in formulations, and integration of digital health solutions are contributing to a more dynamic and patient-centered market. As these developments continue to evolve, they will shape the future of ACE inhibitors and cardiovascular care.

Strategic Growth Opportunities for ACE Inhibitors Market

The ACE inhibitors market is witnessing dynamic growth, with several strategic opportunities emerging across key applications. These opportunities are driven by advancements in medical research, evolving healthcare needs, and increasing global awareness of cardiovascular diseases. By leveraging these growth areas, stakeholders can enhance their market presence and drive innovation. Key applications include hypertension management, heart failure treatment, diabetes-related conditions, stroke prevention, and chronic kidney disease.

• Hypertension Management: Hypertension management remains a primary application for ACE inhibitors. With increasing global hypertension rates, there is a significant opportunity for growth in this sector. Advances in drug formulations, such as extended-release versions, are improving patient adherence and outcomes. The growing awareness and screening programs for hypertension further drive the demand for effective ACE inhibitors, creating a robust market opportunity.
• Heart Failure Treatment: ACE inhibitors are crucial in managing heart failure, a condition that affects millions worldwide. The development of new combination therapies and personalized medicine approaches is expanding treatment options. Innovations in drug delivery and new clinical data demonstrating improved efficacy in heart failure management are enhancing market potential. This growth opportunity is bolstered by the aging population and increasing prevalence of heart failure.
• Diabetes-Related Conditions: ACE inhibitors are increasingly used for managing diabetes-related complications, such as diabetic nephropathy. As the global prevalence of diabetes rises, there is a growing market for ACE inhibitors tailored to diabetes management. Research into the protective effects of ACE inhibitors on kidney function and cardiovascular health is driving this opportunity. Expanding diabetic care programs and increased patient awareness are also contributing factors.
• Stroke Prevention: Preventing stroke through the use of ACE inhibitors is an emerging growth opportunity. Clinical studies highlighting the role of ACE inhibitors in reducing stroke risk, particularly in patients with hypertension or cardiovascular diseases, are paving the way for expanded use. The integration of stroke prevention strategies into broader cardiovascular care programs further supports this market growth.
• Chronic Kidney Disease (CKD): ACE inhibitors play a vital role in managing chronic kidney disease, especially in patients with hypertension and diabetes. As CKD rates increase globally, the demand for ACE inhibitors tailored for renal protection is rising. Advances in research demonstrating the benefits of ACE inhibitors in slowing CKD progression and improving patient outcomes are driving this growth opportunity.

These strategic growth opportunities are reshaping the ACE inhibitors market by expanding applications and improving treatment efficacy. Innovations in drug formulations, personalized medicine, and expanded use in diabetes, stroke prevention, and CKD management are driving market expansion. Leveraging these opportunities can lead to enhanced patient care and significant market growth.

ACE Inhibitors Market Driver and Challenges

The ACE inhibitors market is influenced by a complex interplay of technological, economic, and regulatory factors. Major drivers include advancements in drug development, increasing prevalence of cardiovascular diseases, and supportive healthcare policies. Conversely, challenges such as patent expirations, regulatory hurdles, and market competition impact market dynamics. Understanding these factors is crucial for navigating the evolving landscape of ACE inhibitors.

The factors responsible for driving the ace inhibitors market include:

• Technological Advancements in Drug Development: Technological advancements in drug development, such as new formulations and drug delivery systems, are driving the ACE inhibitors market. Innovations like extended-release formulations and combination therapies enhance drug efficacy and patient compliance. These advancements enable more effective management of conditions like hypertension and heart failure, expanding market opportunities and improving patient outcomes.
• Increasing Prevalence of Cardiovascular Diseases: The rising prevalence of cardiovascular diseases globally is a significant driver for the ACE inhibitors market. As the incidence of hypertension, heart failure, and related conditions grows, the demand for effective ACE inhibitors increases. Public health initiatives and increased awareness are also contributing to higher diagnosis rates and treatment uptake, driving market growth.
• Expanding Geriatric Population: The aging population worldwide is contributing to the growth of the ACE inhibitors market. Older adults are more prone to cardiovascular diseases, leading to higher demand for ACE inhibitors. Healthcare systems are adapting to address the needs of this demographic, creating opportunities for growth in treatments specifically designed for age-related conditions.
• Growing Awareness and Diagnosis: Increased awareness of cardiovascular health and improved diagnostic technologies are driving the demand for ACE inhibitors. Enhanced screening programs and patient education are leading to earlier diagnosis and treatment of hypertension and heart failure. This trend is expanding the market for ACE inhibitors and improving overall patient management.
• Supportive Healthcare Policies: Supportive healthcare policies and regulations in various countries are facilitating market growth. Government initiatives to improve access to cardiovascular treatments and reduce drug costs are benefiting the ACE inhibitors market. Policies that promote research and development in cardiovascular health are also contributing to market expansion and innovation.

Challenges in the ace inhibitors market are:

• Patent Expirations and Generic Competition: Patent expirations for key ACE inhibitors have led to increased competition from generic versions. While generics reduce costs and improve accessibility, they also create pricing pressure on branded drugs. Pharmaceutical companies must navigate this competitive landscape by innovating with new formulations and combination therapies to maintain market share.
• Regulatory Hurdles: Regulatory hurdles, including lengthy approval processes and stringent requirements, pose challenges for new ACE inhibitors. Navigating complex regulatory environments can delay market entry and increase development costs. Companies must invest in regulatory expertise and adapt to varying international regulations to succeed in the global market.
• Market Saturation: The ACE inhibitors market is experiencing saturation due to the availability of multiple generic and branded options. This saturation can lead to reduced profit margins and intensified competition among manufacturers. Companies need to focus on differentiation through innovative formulations and personalized medicine to stand out in a crowded market.

The ACE inhibitors market is shaped by a blend of drivers and challenges. Technological advancements, increasing disease prevalence, and supportive policies are driving growth, while patent expirations, regulatory hurdles, and market saturation present obstacles. Addressing these challenges while leveraging growth drivers will be key to sustaining market expansion and improving patient care.

List of ACE Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ACE Inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ACE Inhibitors companies profiled in this report include-

• AstraZeneca
• Abbott
• Bausch Health Companies
• Pfizer
• AbbVie
• Merck
• Novartis
• Johnson & Johnson
• Sanofi
• Eli Lilly and Company

ACE Inhibitors by Segment

The study includes a forecast for the global ACE Inhibitors market by drug type, application, end use, and region.

ACE Inhibitors Market by Drug Type [Analysis by Value from 2019 to 2031]:

• Lisinopril
• Ramipril
• Captopril
• Moexipril
• Fosinopril
• Perindopril
• Others

ACE Inhibitors Market by Application [Analysis by Value from 2019 to 2031]:

• Heart Failure
• Hypertension
• Chronic Kidney Disease
• Diabetes
• Others

ACE Inhibitors Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmacies
• Online Drug Stores
• Others

ACE Inhibitors Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the ACE Inhibitors Market

The ACE (angiotensin-converting enzyme) Inhibitors market has been evolving rapidly due to advancements in pharmaceutical research, shifts in healthcare policies, and increasing demand for effective hypertension and heart failure treatments. Key markets such as the United States, China, Germany, India, and Japan have seen diverse developments that reflect their unique healthcare needs and regulatory environments. These developments include innovations in drug formulations, changing market dynamics, and new regulatory approvals, each contributing to the global landscape of ACE inhibitors.

• United States: In the U.S., recent developments in the ACE inhibitors market include the introduction of new generic versions and extended-release formulations. The FDA has approved several new generics, which has intensified competition and lowered costs for patients. Additionally, advancements in drug delivery technologies have led to improved patient compliance. The growing prevalence of hypertension and heart disease has further spurred market growth, supported by increased healthcare expenditure and comprehensive insurance coverage for cardiovascular treatments.
• China: China's ACE inhibitors market has been marked by a surge in local pharmaceutical companies producing generics. The National Medical Products Administration (NMPA) has streamlined approval processes, enhancing market entry for these generics. There is also a growing focus on addressing hypertension due to the rising prevalence of cardiovascular diseases. The Chinese government's healthcare reforms and increasing investment in chronic disease management are driving the demand for more affordable and effective ACE inhibitors in the country.
• Germany: In Germany, the ACE inhibitors market is influenced by the country's robust healthcare system and emphasis on evidence-based medicine. Recent developments include increased adoption of combination therapies that include ACE inhibitors, targeting broader patient demographics. The market has also seen a rise in the use of ACE inhibitors in preventive cardiology. Regulatory bodies, such as the Federal Institute for Drugs and Medical Devices (BfArM), have been proactive in approving new formulations and generics, ensuring a competitive market.
• India: India's ACE inhibitors market is expanding due to growing awareness and diagnosis of hypertension and related cardiovascular conditions. Recent developments include the introduction of new generic ACE inhibitors and partnerships between local companies and multinational pharmaceutical firms. The Indian government's focus on affordable healthcare and the implementation of price control measures have made ACE inhibitors more accessible. Additionally, increased public health campaigns and improvements in healthcare infrastructure are driving market growth.
• Japan: In Japan, the ACE inhibitors market is seeing innovation in drug formulations and combination therapies, reflecting the country's advanced medical research. The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved several new ACE inhibitors and generics, contributing to market expansion. The aging population and increasing prevalence of cardiovascular diseases are driving demand. Furthermore, there is a growing focus on personalized medicine, with new ACE inhibitors being developed to cater to specific genetic profiles and patient needs.

Features of the Global ACE Inhibitors Market

Market Size Estimates: Ace inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Ace inhibitors market size by drug type, application, end use, and region in terms of value ($B).

Regional Analysis: Ace inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, application, end use, and regions for the ACE Inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ACE Inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ACE Inhibitors market by drug type (lisinopril, ramipril, captopril, moexipril, fosinopril, perindopril, and others), application (heart failure, hypertension, chronic kidney disease, diabetes, and others), end use (hospitals, pharmacies, online drug stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global ACE Inhibitors Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global ACE Inhibitors Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global ACE Inhibitors Market by Drug Type
  • 3.3.1: Lisinopril
  • 3.3.2: Ramipril
  • 3.3.3: Captopril
  • 3.3.4: Moexipril
  • 3.3.5: Fosinopril
  • 3.3.6: Perindopril
  • 3.3.7: Others
• 3.4: Global ACE Inhibitors Market by Application
  • 3.4.1: Heart Failure
  • 3.4.2: Hypertension
  • 3.4.3: Chronic Kidney Disease
  • 3.4.4: Diabetes
  • 3.4.5: Others
• 3.5: Global ACE Inhibitors Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Pharmacies
  • 3.5.3: Online Drug Stores
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global ACE Inhibitors Market by Region
• 4.2: North American ACE Inhibitors Market
  • 4.2.1: North American Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
  • 4.2.2: North American Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
• 4.3: European ACE Inhibitors Market
  • 4.3.1: European Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
  • 4.3.2: European Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
• 4.4: APAC ACE Inhibitors Market
  • 4.4.1: APAC Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
  • 4.4.2: APAC Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
• 4.5: ROW ACE Inhibitors Market
  • 4.5.1: ROW Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
  • 4.5.2: ROW Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global ACE Inhibitors Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global ACE Inhibitors Market by Application
  • 6.1.3: Growth Opportunities for the Global ACE Inhibitors Market by End Use
  • 6.1.4: Growth Opportunities for the Global ACE Inhibitors Market by Region
• 6.2: Emerging Trends in the Global ACE Inhibitors Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global ACE Inhibitors Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global ACE Inhibitors Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AstraZeneca
• 7.2: Abbott
• 7.3: Bausch Health Companies
• 7.4: Pfizer
• 7.5: AbbVie
• 7.6: Merck
• 7.7: Novartis
• 7.8: Johnson & Johnson
• 7.9: Sanofi
• 7.10: Eli Lilly and Company International